A significant BCR-ABL vaccination effect was described in a 63-year-old woman with CML relapse after interferon (IFN)-α treatment who achieved a complete cytogenetic response for 6 years. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.